Natco Pharma to raise stake in Adcock Ingram to 49% with ₹1,400 crore investment

Share:

The board of directors of Natco Pharma has approved the acquisition of an additional shareholding in Adcock Ingram Holdings Proprietary Ltd with an investment of up to ₹1400 crore.

This acquisition is valued at ₹1,069 crore at the prevailing exchange rate and will take Hyderabad-based Natco's shareholding in Adcock Ingram from 35.75 percent to 49 percent, the company said in a emit.

Adcock Ingram has delivered a topline of $423 million with an EBITDA of $59 million to the period ending 9 months on March 31, 2026. Post transaction, NATCO will be recognising 49 percent of profit after tax of Adcock Ingram in its books.

Published on July 8, 2026

Previous

Oversupply of China Ethylene Glycol Likely to Persist in the Medium Term

Next

China PA6 Market Hits Bottom and Rebounds Slightly

Quick inquiry

Create

Inquiry Sent

We will contact you soon